PMID- 36414094 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20240102 IS - 1872-8294 (Electronic) IS - 0169-409X (Print) IS - 0169-409X (Linking) VI - 192 DP - 2023 Jan TI - Delivering on the promise of recombinant silk-inspired proteins for drug delivery. PG - 114622 LID - S0169-409X(22)00512-9 [pii] LID - 10.1016/j.addr.2022.114622 [doi] AB - Effective drug delivery is essential for the success of a medical treatment. Polymeric drug delivery systems (DDSs) are preferred over systemic administration of drugs due to their protection capacity, directed release, and reduced side effects. Among the numerous polymer sources, silks and recombinant silks have drawn significant attention over the past decade as DDSs. Native silk is produced from a variety of organisms, which are then used as sources or guides of genetic material for heterologous expression or engineered designs. Recombinant silks bear the outstanding properties of natural silk, such as processability in aqueous solution, self-assembly, drug loading capacity, drug stabilization/protection, and degradability, while incorporating specific properties beneficial for their success as DDS, such as monodispersity and tailored physicochemical properties. Moreover, the on-demand inclusion of sequences that customize the DDS for the specific application enhances efficiency. Often, inclusion of a drug into a DDS is achieved by simple mixing or diffusion and stabilized by non-specific molecular interactions; however, these interactions can be improved by the incorporation of drug-binding peptide sequences. In this review we provide an overview of native sources for silks and silk sequences, as well as the design and formulation of recombinant silk biomaterials as drug delivery systems in a variety of formats, such as films, hydrogels, porous sponges, or particles. CI - Copyright (c) 2022 Elsevier B.V. All rights reserved. FAU - Gonzalez-Obeso, Constancio AU - Gonzalez-Obeso C AD - Department of Biomedical Engineering, Tufts University, 4 Colby Street, Medford, Massachusetts 02155, USA. FAU - Jane Hartzell, Emily AU - Jane Hartzell E AD - Department of Biomedical Engineering, Tufts University, 4 Colby Street, Medford, Massachusetts 02155, USA. FAU - Albert Scheel, Ryan AU - Albert Scheel R AD - Department of Biomedical Engineering, Tufts University, 4 Colby Street, Medford, Massachusetts 02155, USA. FAU - Kaplan, David L AU - Kaplan DL AD - Department of Biomedical Engineering, Tufts University, 4 Colby Street, Medford, Massachusetts 02155, USA. Electronic address: david.kaplan@tufts.edu. LA - eng GR - P41 EB027062/EB/NIBIB NIH HHS/United States GR - R01 NS094218/NS/NINDS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, P.H.S. PT - Review DEP - 20221119 PL - Netherlands TA - Adv Drug Deliv Rev JT - Advanced drug delivery reviews JID - 8710523 RN - 0 (Recombinant Proteins) RN - 0 (Biocompatible Materials) SB - IM MH - Humans MH - *Drug Delivery Systems MH - Recombinant Proteins MH - *Biocompatible Materials/chemistry PMC - PMC9812964 MID - NIHMS1855168 OTO - NOTNLM OT - Biomaterials OT - Cancer therapy OT - Silk-like proteins OT - Tissue regeneration OT - Wound healing COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/11/23 06:00 MHDA- 2023/01/04 06:00 PMCR- 2024/01/01 CRDT- 2022/11/22 19:23 PHST- 2022/08/20 00:00 [received] PHST- 2022/11/06 00:00 [revised] PHST- 2022/11/14 00:00 [accepted] PHST- 2022/11/23 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/11/22 19:23 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - S0169-409X(22)00512-9 [pii] AID - 10.1016/j.addr.2022.114622 [doi] PST - ppublish SO - Adv Drug Deliv Rev. 2023 Jan;192:114622. doi: 10.1016/j.addr.2022.114622. Epub 2022 Nov 19.